Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience
Background Direct-acting antivirals (DAA) are currently used for the treatment of chronic hepatitis C (HCV). However, few studies describe the adverse effects (AE) associated with DAA therapy in “real-word” cohorts. Aim To evaluate AE in Brazilian chronic HCV patients after DAA-therapy. Setting A reference center for hepatitis treatment in Rio de Janeiro, Brazil. Methods An observational “real-world” study was conducted with 102 chronic HCV patients undergoing DAA therapy for 12 or 24 weeks. The self-reported AE were correlated with cirrhosis status, genotype, age, current therapeutic schemes and comorbidities. Serious AE were also investigated. Main outcome measure Frequency of AE during DAA therapy. Results Overall, mean ± SD age was 60.9 ± 9.4 years, 67% were females, HCV-genotype 1 was the most prevalent (81%) and 74% were cirrhotic. Moreover, all patients reached sustained virological response. About 90% of patients reported at least one AE associated with current treatment, with a mean of 2.7 symptoms per patient. The most frequently reported AE were fatigue (43%), headache (42%), neuropsychiatric symptoms (30%) and nausea (26%). Furthermore, hemoglobin < 12 mg/dL was the most frequent (38%) laboratory abnormality observed. Neuropsychiatric symptoms were the only AE significantly different in treatment-experienced group when compared to naïve patients (41.7 vs. 12.5, P = 0.002). The higher frequency of AE did not correlate with the presence of previous treatment, cirrhosis, genotype, age, current therapeutic schemes with DAA or comorbidities. Conclusion DAA-based therapeutic regimens demonstrated safety in a Brazilian “real-world” cohort of chronic hepatitis C patients.
KeywordsAdverse effects Brazil Chronic hepatitis C Direct-acting antiviral Sofosbuvir
End of treatment
Hepatitis C virus
Serious adverse effects
Sustained virological response
The authors thank to the Unidade de Pesquisa Clínica and the Serviço de Patologia Clínica (UFF) by technical support.
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES): T. Medeiros, N.F. Rosário, G.N. Saraiva are students fellow.
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro/FAPERJ (JCNE/E-26/102.173/2013): A.A. Silva is a research fellow.
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 1.Brazil. Ministry of health. Clinical protocol and therapeutic guidance for hepatitis C and coinfections. Brasilia; 2015.Google Scholar
- 6.Guglieri-López B, Ventura-Cerdá JM, Gómez-Álvarez S, Climente-Martí M. Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment. Enferm Infecc Microbiol Clin. 2015;33(5):331–6.CrossRefPubMedGoogle Scholar
- 16.Brazil. Ministry of health. 1° Seminar on participatory management forum of municipal health councils of metropolitan region II. Brasilia; 2007.Google Scholar
- 18.Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: a systematic review and network meta-analysis. PLoS ONE. 2015;10(12):e0145953.CrossRefPubMedPubMedCentralGoogle Scholar